New research indicates that people who come off popular GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who stop conventional lifestyle plans.
Published data in a major medical journal points out that while obese people often shed substantial amounts of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month after stopping.
"Users purchasing such medications need to be aware of the risk of rapid weight regain when the medication is stopped," cautioned expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight within about 18 months.
Analyzing Approaches
The study, which looked at dozens of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with older methods.
Scientists point out that people who shed pounds through dieting typically have a more gradual weight regain—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Nutrition scientists propose the mode of action of the jabs explains the accelerated regain.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal could lead to the system to produce less of its endogenous GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication means hunger is uncontrolled, making overeating far more likely."
A Lifelong Condition?
Medical guidelines advise the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Professionals argue that, due to the high risk of weight regain, the therapy should be considered long-term.
This perspective is reinforced by pharmaceutical companies, who note that the findings "highlight the long-term nature of obesity," similar to managing conditions like hypertension.
User Testimonies
Individuals who have discontinued the medication report a intense return of cravings.
"I experienced a trigger activating and you become ravenous," recalled an individual.
This challenge is compounded if users have not established permanent lifestyle or habit modifications during therapy.
Widespread Use
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.
- Use is more common among women than men.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, researchers emphasize that while the jabs are potent agents for shedding pounds, they are not a magic fix and maintained weight loss hinges on integrated lifestyle management.
